Endothelin receptor antagonists in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Endothelins are peptide compounds regulating cellular processes like growth, survival, invasion, and angiogenesis.
• Endothelin-1, via the endothelin-A receptor, is linked to neoplastic growth in various tumors.
• Preclinical studies show endothelin antagonism inhibits tumor proliferation, invasion, angiogenesis, and tumor-related bone/pain responses.

Purpose of the Study:

• To evaluate the efficacy of an orally bioavailable endothelin antagonist in men with prostate cancer.
• To assess the drug's impact on prostate-specific antigen (PSA) progression, bone turnover markers, and pain.
• To determine the potential role of endothelin antagonists in targeted anti-cancer therapy.

Main Methods:

• Clinical testing of an orally bioavailable endothelin antagonist.
• Monitoring of PSA progression, bone turnover markers, and pain levels in patients.
• Evaluation of survival and time to cancer progression.

Main Results:

• The endothelin antagonist demonstrated benefits in PSA progression, bone turnover markers, and pain.
• Significant improvement in overall survival or time to cancer progression was not observed.
• Preclinical models indicated inhibition of tumor cell proliferation, invasiveness, and angiogenesis.

Conclusions:

• Endothelin antagonism shows potential as a targeted anti-cancer therapy, particularly in prostate cancer.
• While beneficial for certain markers and symptoms, the drug's impact on survival requires further investigation.
• Completion of future clinical trials is essential to define the definitive role of endothelin antagonists in cancer treatment.